IP Library Granted Patent US 9,289,481
Granted Patent B2
US 9,289,481 · App. 12/560,321 · Granted Mar 22, 2016

Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression

Inventors: Janakiraman Ramachandran (Palo Alto, CA); Sriram Padmanabhan (Sanjaynagar, IN); Bharathi Sriram (Sanjaynagar, IN)
Assignee: Gangagen, Inc.
A61K39/02A61K39/0258A61K2039/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,289,481
App. No.
12/560,321
Granted
Mar 22, 2016
Kind
B2
Abstract

The present invention features incapacitated whole-cell bacterial immunogenic compositions and methods of their production, which compositions are useful to deliver antigens in a manner resembling the live infectious organism in terms of elicitation of a robust immune response, but with reduced risk or no risk of disease. The compositions of the invention are produced by rendering a bacterium bacteriostatic through expression of a recombinant promoter in the bacterial cell, which promoter can be operably linked to a polynucleotide encoding a recombinant gene product. In one embodiment, where the bacterium is a gram negative host, the recombinant gene product provides for reduced toxicity of LPS. In one embodiment, the gene product is a bacteriophage protein, such as endolysin, holin, or ndd.

Claims (13)

1. A method of immunizing a subject against a bacterial pathogen, the method comprising:

administering to the subject an incapacitated immunogenic bacterial composition comprising the bacterial pathogen carrying an expression vector comprising a recombinant promoter operably linked to a polynucleotide encoding a gene product,

wherein the recombinant promoter is a bacteriophage promoter, and wherein the bacterial pathogen is recombinantly modified to express a bacteriophage RNA polymerase for transcription from the bacteriophage promoter,

wherein expression of the gene product is at a level sufficient to render the bacterial pathogen incapacitated, thereby producing said incapacitated immunogenic bacterial composition,

wherein administration of said incapacitated immunogenic bacterial composition elicits an immune response to an antigen on the bacterial pathogen, thereby immunizing the subject against the bacterial pathogen, and

wherein

(i) the bacteriophage promoter is a T7 bacteriophage promoter and the bacteriophage RNA polymerase is T7 RNA polymerase,

(ii) the bacteriophage promoter is a SP6 bacteriophage promoter and the bacteriophage RNA polymerase is SP6 RNA polymerase,

(iii) the bacteriophage promoter is a T3 bacteriophage promoter and the bacteriophage RNA polymerase is T3 RNA polymerase, or

(iv) the bacteriophage promoter is a T7 bacteriophage promoter and the bacteriophage RNA polymerase is T7 RNA polymerase.

2. The method of claim 1 , wherein the bacterial pathogen is of a genus selected from the group consisting of Bordetella , Mycobacteria, Staphylococci, Vibrio, Enterobacter, Enterococcus, Escherichia, Haemophilus, Neisseria, Pseudomonas, Shigella, Serratia, Salmonella, Streptococcus, Klebsiella and Yersinia.

3. The method of claim 1 , wherein the expression cassette is on a plasmid.

4. The method of claim 1 , wherein the bacterial pathogen is Escherichia coli or Staphylococcus aureus .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 052603/0390 →
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2020
From: ATEL VENTURES, INC.
To: GANGAGEN, INC.
Reel/Frame 051507/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2020
From: GANGAGEN, INC.
To: BACTOCLEAR HOLDINGS PTE. LTD.
Reel/Frame 051499/0244 →
SECURITY INTEREST Recorded Jul 26, 2018
From: GANGAGEN, INC.
To: ATEL VENTURES, INC.
Reel/Frame 046475/0531 →
Continuity (3)
Continuation 10715348 · Nov 14, 2003
Provisional Application 60426670 · Nov 14, 2002
Related Publication 20100303862A1 · Dec 2, 2010